PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications - Candlesense
PMCB Investments

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

(NASDAQ:PMCB) LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an additional $3 million. The Company does so to help support TNF’s recent acquisition of a license with LightSolver, Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed

Related Questions

What impact could the Light Speed Computing platform’s exposure to cryptocurrency applications have on the valuation and risk profile of both PMCB and TNFA relative to peers? What regulatory, adoption and competitive risks are associated with the new accelerator technology, and how might they influence the stocks' price trajectories? How will PharmaCyte's increased $3 million stake in TNF and the LightSolver licensing deal affect its near‑term earnings and cash flow?
Find similar articles on Candlesense businesswire